Clinical Trial Update: A Study of ES102 (OX40 Agonist) in Combination With JS001 in Patients With Advanced Solid Tumors [Phase 1]

View source ↗

Summary

This Phase 1 trial evaluating ES102, an OX40 agonist, in combination with JS001 in patients with advanced solid tumors has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Malignant Tumor
• Neoplasms
• Solid Tumor

Drugs mentioned

• ES102 (ES102)
• JS001 (PD-1 inhibitor)

Snippet

Sponsor: Elpiscience Biopharma, Ltd. | Conditions: Solid Tumor, Neoplasms | Phase 1 | Status: COMPLETED